Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/22/2020 05/26/2020 05/27/2020 05/28/2020 05/29/2020 Date
60.79(c) 60.32(c) 60.4(c) 59.81(c) 59.72(c) Last
9 228 647 18 447 833 19 071 687 14 977 982 25 408 139 Volume
-0.57% -0.77% +0.13% -0.98% -0.15% Change
More quotes
Financials (USD)
Sales 2020 41 932 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 322 M - -
P/E ratio 2020 114x
Yield 2020 2,99%
Sales 2021 45 377 M - -
Net income 2021 7 444 M - -
Net Debt 2021 22 512 M - -
P/E ratio 2021 11,2x
Yield 2021 3,15%
Capitalization 135 B 135 B -
EV / Sales 2020 3,87x
EV / Sales 2021 3,47x
Nbr of Employees 30 000
Free-Float 77,3%
More Financials
Company
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Products are intended for the treatment of cancers, cardiovascular diseases, hepatitis, immune diseases and psychiatric disorders. Net sales are distributed geographically as follows: the United States (58.7%), Europe (24%) and other (17.3%). 
Sector
Pharmaceuticals
Calendar
05/29Presentation
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
05/29BRISTOL MYERS SQUIBB : to Hold Virtual Three-Part Investor Series
BU
05/28BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia for the..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
AQ
05/27BRISTOL MYERS SQUIBB : Gets European Union Approval for MS Drug Zeposia
DJ
05/27BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia (ozanim..
BU
05/26BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo® (nivol..
BU
05/25BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb'..
AQ
05/22Bristol Myers Says EMA Validates Applications for Idecabtagene Vicleucel, CC-..
DJ
05/22BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb'..
BU
05/21ACCELERON PHARMA : Announces Presentations on REBLOZYL at the 2020 American Soci..
AQ
05/20BRISTOL MYERS SQUIBB : Research at EHA 2020 Demonstrates Continued Advances Acro..
BU
05/19BRISTOL MYERS SQUIBB CO : Other Events, Financial Statements and Exhibits (form ..
AQ
05/18BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
AQ
05/18BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Bristol Myers ..
AQ
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPA
05/29BRISTOL MYERS SQUIBB : to Hold Virtual Three-Part Investor Series
05/28BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia for the..
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
05/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
05/27BRISTOL MYERS SQUIBB : Gets European Union Approval for MS Drug Zeposia
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPA
More recommendations
Stock Trading Strategies
BRISTOL-MYERS SQUIBB COMPANY - 2019
The beginning of the move
BUY
More Stock Trading Analysis
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 67,34 $
Last Close Price 59,72 $
Spread / Highest target 39,0%
Spread / Average Target 12,8%
Spread / Lowest Target -89,7%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.96%135 331
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274